logo
Twitter
Discord
Email
logo
Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ•CRBP
CEO: Dr. Yuval Cohen Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-10-27
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Contact Information
500 River Ridge Drive, Norwood, MA, 02062, United States
617-963-0100
www.corbuspharma.com
Market Cap
$109.43M
P/E (TTM)
-1.6
37
Dividend Yield
--
52W High
$20.56
52W Low
$4.64
52W Range
26%
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$1.90+65.22%
4-Quarter Trend

FCF

-$15.55M+11.53%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Strengthened Total cash, equivalents, restricted cash reached $27.7 M at September 30, 2025, up $9.8 M from year-end 2024.
Major Equity Financing Closed Completed $75.0 M gross proceeds public offering in November 2025, securing operating runway for clinical development.
R&D Spending Surges Research and development expenses grew 121% to $51.7 M for nine months, supporting CRB-701 and CRB-601 trials.

Risk Factors

Accelerating Net Loss Net loss widened to $(58.0) M for nine months, nearly doubling prior year's $(30.7) M loss due to increased spending.
High Operating Expense Growth Total operating expenses grew 75% to $63.3 M for nine months, driven primarily by escalating clinical trial costs.
Pre-Revenue Dependency Company remains clinical-stage, generating zero revenue, dependent on external capital to fund operations and development.
Equity Value Erosion Total stockholders' equity decreased to $92.1 M; future financing may result in significant dilution to existing shareholders.

Outlook

CRB-701 Registrational Planning Expect to engage FDA mid-2026 regarding the design of a registrational study for the lead oncology candidate CRB-701.
Obesity Trial Initiation Obesity candidate CRB-913 expected to initiate a Phase 1b dose-range finding study in obese non-diabetic individuals in Q4 2025.
Future Capital Requirements Requires significant additional capital to fund ongoing pre-clinical and clinical trials for all three pipeline product candidates.

Peer Comparison

Revenue (TTM)

Genfit S.A.GNFT
$126.71M
+9.8%
Codexis, Inc.CDXS
$52.93M
-17.9%
Invivyd, Inc.IVVD
$50.04M
+243.0%

Gross Margin (Latest Quarter)

Genfit S.A.GNFT
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+4.3pp
Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
GNFT$309.74M-7.1-63.7%64.1%
IVVD$280.06M-6.0-93.0%1.9%
TARA$238.87M-4.9-35.1%2.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 10, 2026
|
EPS:-$1.78
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.90+65.2%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.44-59.4%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.39-43.3%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.68+64.3%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.15-49.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.55+73.2%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.45-42.2%
    N/A

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 20, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-10.31-1.6%
    N/A